Vitamin D deficiency: The 'constant' feeling which may indicate a deficiency
VITAMIN D helps regulate the amount of calcium and phosphate in the body, so a lack of it can lead to a number of issues. Some signs of deficiency can be somewhat vague, while others may only occur if you have been lacking the vitamin for some time. (Source: Daily Express - Health)
Source: Daily Express - Health - February 12, 2022 Category: Consumer Health News Source Type: news
CAC scores predict cardiac risk in patients with high cholesterol
Patients with elevated LDL-C levels but with low coronary artery calcium score...Read more on AuntMinnie.comRelated Reading:
CCTA plaque data improve heart disease risk assessment in diabetics
Are radiologists regaining control of cardiac imaging?
CTA shows how statin treatment changes coronary plaque
CTA shows the effect of job stress on the heart
Use of CTA, CT perfusion up -- but for the right reasons (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 11, 2022 Category: Radiology Source Type: news
Dr Reddy's inks exclusive sales pact with Novartis India
Under the arrangement, Dr Reddy's will have exclusive rights to promote and distribute the well-established Voveran range, the Calcium range and Methergine in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 11, 2022 Category: Pharmaceuticals Source Type: news
Vitamin D deficiency: The sign when you wake up which is 'an early' indicator
VITAMIN D is crucial for your health, because it helps regulate the amount of calcium and phosphate in the body. This is necessary for keeping bones and teeth healthy. (Source: Daily Express - Health)
Source: Daily Express - Health - February 8, 2022 Category: Consumer Health News Source Type: news
Clinimix E (Amino Acids with Electrolytes in Dextrose with Calcium Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2022 Category: Drugs & Pharmacology Source Type: news
Evaluation of the ability of adhesives with antibacterial and remineralization functions to prevent secondary caries in vivo
ConclusionsThe NACP-DMAHDM-containing adhesive exhibited good performance in preventing secondary caries in vivo.Clinical relevanceAdhesives containing NACP and DMAHDM have great potential for use in clinical dentistry to prevent secondary caries by inhibiting bacterial growth and promoting remineralization. (Source: Dental Technology Blog)
Source: Dental Technology Blog - January 29, 2022 Category: Dentistry Source Type: news
Vitamin deficiency: ‘One in five are lacking an essential’ nutrient – symptoms
"ONE in five" Britons suffer from vitamin D deficiency, which is "essential" for various functions in the body. For example, it helps to regulate the amount of calcium and phosphate. This in return helps to keep your bones, teeth and muscles healthy. New research shared that many Britons are "unclear" about vitamin D's benefits and deficiency symptoms. Here are the warning signs to spot. (Source: Daily Express - Health)
Source: Daily Express - Health - January 19, 2022 Category: Consumer Health News Source Type: news
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.“Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high. Our relentless pursuit of treatments ...
Source: Johnson and Johnson - December 29, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news
The effect of various fluoride products on dentine lesions during pH-cycling
In conclusion, all topical fluoride products protected the dentine lesions against lesion progression, but at different degrees. SDF showed a superior effect in protection against further demineralization and enhancement of remineralization. This was probably attributed to its fluoride concentration that was the highest among the fluoride products. (Source: Dental Technology Blog)
Source: Dental Technology Blog - December 28, 2021 Category: Dentistry Source Type: news
Coronary Calcium Better Predictor of Need for Statin Than Equations Coronary Calcium Better Predictor of Need for Statin Than Equations
A feasibility study shows coronary artery calcium scanning has the potential to better target patients who require statin therapy than the current standard of pooled cohort equations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 21, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Vitamin D Counters Bone Density Loss With Aromatase Inhibitors Vitamin D Counters Bone Density Loss With Aromatase Inhibitors
Among women with breast cancer being treated with aromatase inhibitors, supplementation with vitamin D and calcium protected against bone loss after 5 years.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the RP2D,...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma. The data, featured as an oral presentation at the American Society of Hematology (ASH) 2021 Annual Meeting (Abstract #549) and selected as part of the Highli...
Source: Johnson and Johnson - December 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) Pha...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also be featured...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
